The conjugation of carbohydrates to synthetic scaffolds has the goal of preparing potent inhibitors of lectin binding. We herein report the synthesis of a panel of bivalent compounds (cyclophane and terephthalamide-derivatives) then used to establish the influence of scaffold flexibility on respective inhibitory potency in a medically relevant test system. Synthetic routes to two phenylenediamine-based glycocyclophanes involving Ugi reactions of glucuronic acid derivatives and subsequent ring closing metathesis are described, as are improvements for producing terephthalamide-based carbohydrate carriers. Assays were performed with human tumour cells measuring quantitatively the influence of the test compounds on fluorescent surface staining by labelled lectins. Biological evaluation using two different lines of cancer cells as well as cells with known alterations in the glycomic profile (cells treated with an inhibitor of glycan processing and a glycosylation mutant) reduced the risk of generating premature generalizations regarding inhibitor potency. Bioactivity relative to free mannose was invariably determined for the synthetic compounds. A clear trend for enhanced inhibitory properties for macrocyclic compounds compared to non-macrocyclic derivatives was discerned for one type of glycocyclophane. Herein we also document the impact of altering the spacing between the mannose residues, altering cell surface ligand density and cell-type reactivity. The applied strategy for the cell assays is proposed to be of general importance in the quest to identify medically relevant lectin inhibitors.
Introduction
The ideal chemical properties of carbohydrates to generate an unsurpassed structural biodiversity of oligomers and to engage in intermolecular interactions underlie the concept of the sugar code.
1 Indeed, glycans of cell surface glycoproteins are versatile biochemical signalling molecules by serving as direct contact site for receptors with carbohydrate specificity (trans-interactions) and as potent molecular switches regulating the protein component's accessibility and functionality (cis-interactions).
1,2 Even seemingly minor structural changes in these complex carbohydrates, such as a core substitution in N-glycans, trigger significant alterations in glycan conformations and lectin affinity.
3 Underlining their salient role for cellular communication, several cases have been elucidated in which orchestrated changes in glycan display and expression of the cognate lectin cooperate to turn sugar-encoded information swiftly into cellular responses such as apoptosis induction or autoimmune suppression.
4 Considering the multiple, medically relevant activities of cell surface glycans in regulating e. g. adhesion, migration, proliferation or tissue invasion, it is an attractive aim to develop strategies to efficiently interfere with the binding of certain effectors to cell surface glycans. In other words, the issue to define structure-activity relationships for lectinblocking compounds is of fundamental importance, especially at the level of cell surfaces which represent the physiological platform for the interaction process. Toward this end, we herein put the question to the experimental test whether and how intramolecular flexibility of distinct scaffolds carrying two docking sites for a model lectin affects its cell surface binding. In detail, we compare two rather flexible bivalent compounds (1a, 3a) with the corresponding rigid glycocyclophanes (2a, 4a/4b) ( Fig. 1) , the central synthetic and cell biological part of our report. In addition, other phenylenediamine-based bivalent compounds (5a, 10) and the monovalent compound (6a) were used as controls (Fig. 1) . The impact of scaffold design on bioactivity is further evaluated by testing four bivalent terephthalamide-based compounds (7c, 7d, 8, 9) 5 and the bivalent mannoside 11, based on a tetraethylene glycol scaffold (Fig. 1) . The selection of the bivalent ligand systems was based on choosing scaffolds with varying degrees of rigidity with a view to exploring how changing both rigidity and the spatial presentation of ligand would alter inhibition of lectin binding. The spatial relationship between the two mannose ligands in the two most constrained systems 2a and 4a is shown to be significantly different. The linkage patterns of the mannose ligands and thus spatial relationship between these residues is also different when comparing the terephthalamides 7-9, of which the initial synthetic and structural aspects were reported previously.
5 Since glycan display on cells is physiologically subject to dynamic changes, the design of suitable assays is a key factor to assess inhibitory capacity of any compound. It should account for shifts in the glycomic profile to reach valid conclusions. Consequently, our respective efforts were guided by the intention to introduce systems with deliberately tunable affinity and density of cell surface ligands with a view to evaluating glycocompound potency. Naturally, these two characteristics can have a bearing on the competition between the synthetic agent and cell surface glycans for binding to the lectin. Thus, a more general inhibitory trend for a synthetic ligand warrants being investigated and this can be achieved by adequate tailoring of the test system. Toward this aim, treatment of cells with an inhibitor of glycan processing as well as using a cell type expressing a suitable glycosylation mutant 2g are both viable options to alter glycomic profile by altering N-glycan structure on the cell surface. Hereby, the cell surface density of mannose residues and the presentation of truncated complex-type N-glycans, respectively, are increased. These changes will enhance binding of the test lectin concanavalin A (ConA), facilitating inhibitory assays using cells with different glycomic profiles. In detail, the binding of the labelled lectin to native cells is monitored automatically on the single-cell level by fluorescent staining, and an inhibitor, blocking lectin-binding, will decrease staining intensity.
Experimentally, the lectin's binding parameters to cells (mean fluorescence intensity of stained cells and percentage of positive cells) and reactivity to inhibitors were determined for two different human tumour cell lines to trace cell-type-dependent alterations. If the sugar derivatives maintain their bioactivity, then the presence of a glycocompound will reduce fluorescent cell surface staining by the labelled lectin, and these activities are routinely compared to that of free mannose as the reference value. The two approaches to cell surface ligand remodelling then enabled to derive a relationship between the observed inhibitory activity observed for a synthetic compound to changes in the profile of N-glycans. More specifically, we shifted the glycomic profile of one tumour cell system to high-mannose-type N-glycans by applying the mannosidase I inhibitor 1-deoxymannojirimycin and additionally tested the glycosylation mutant Lec8 of the Chinese hamster ovary system. The latter presents high-affinity ligands for ConA constituted by the N-acetylglucosamine (GlcNAc)-terminated trimannoside core.
6

Results and discussion
Synthesis
The various rigid and flexible compounds 1-5 for the presentation of the mannose ligand were envisaged to be accessible via Ugi reactions of glucuronic acid derivatives. As the first step, the syntheses of required building blocks (14, 18, 19) were carried out.
In detail, the glycosidation of trichloroacetimidate 12 7 promoted by boron trifluoride etherate in the presence of allyl alcohol generated the allyl glycoside with b-configuration. Saponification and subsequent treatment of the product with acetic anhydride gave a 6,3-lactone derivative as an intermediate. This lactone was converted to 13 [17] [18] [19] by reaction with allyl alcohol in presence of molecular sieves and sodium acetate. Glycoside bond-forming reaction of 13 with the Schmidt-Michel donor 15 8 gave the expected a-glycoside product in good yield, and subsequent selective hydrolysis of the allyl ester using Pd (0) catalysis 9 resulted in 14 (Scheme 1).
Scheme 1 Synthesis of 14.
The a-glycoside 16, prepared as described previously, 10 was treated with sodium methoxide in MeOH, then acetylation produced a 6,3-lactone derivative analogous to 12, except for its a-configuration. Subsequent reaction of this lactone intermediate with allyl alcohol in the presence of molecular sieves and sodium acetate produced glycosyl acceptor 17. Glycosidation using the trichloroacetimidate donor 15 and subsequent Pd (0)-catalysed hydrolysis of the allyl ester as before gave 18 (Scheme 2). The azide derivative 19 was prepared by literature procedure.
5d
With these carboxylic acid derivatives in hand we were able to generate divalent structures using Ugi reactions. This approach to the bivalent tertiary anilides was superior to other routes investigated. The less successful routes included amide coupling reactions of 1,4-phenylenediamine with glucuronic acid derivatives and efforts to subsequently alkylate the amides. In contrast, the Ugi reactions of 14, 18 and 19 with formaldehyde, phenylene-1,4-diamine and methyl isocyanoacetate proceeded efficiently to give 20a-22b (Scheme 3). The N-butyl derivative 21b (structure shown in Scheme 4) was obtained from the corresponding Ugi reaction of 18 with n-butylisocyanide. Removal of ester-protecting groups from 20a-22b proved difficult due to competing cleavage of the tertiary anilides. The hydrolysis product 6a, for example, was generated from attempts to convert 20a into 1a using a variety of conditions, including Zemplén deacetylation. The use of triethylamine in the presence of water and MeOH or KCN- MeOH did ultimately give the bivalent mannosides 1a (18%), 3a (25%) and 5a (8%) in low yields (Scheme 3).
With the mannose derivatives 20a and 21a/21b in hand macrocyclisation was effected using ring-closing metathesis reactions, generating conformationally constrained macrocyclic structures (Scheme 4). The reaction of 20a with the Grubbs-I catalyst (91%), subsequent catalytic hydrogenolysis (89%) and de-O-acetylation using KCN in MeOH (11%) gave 2a (not shown). As in the synthesis of acyclic derivatives 1a and 3a (Scheme 3), it was not possible to prevent competing cleavage of the tertiary anilide intermediate, which was the major reason for the low yields of the desired macrocyclic glycocyclophane derivatives. A similar sequence from 21a and 21b gave 4a and 4b (Scheme 4), respectively. The yield for the deprotection of the ring-closed product obtained from metathesis of 21b, which was achieved with triethylamine in MeOH and water, was higher than that observed for deprotection of the ring-closed product obtained from 21a, which involved use of KCN-MeOH.
The synthesis of terephthalamide derivative 7d, adding to prior experience, 5c was accomplished from diacetone-D-glucose 23 (Scheme 5). Glycosidation of 23 using 15 as donor and with Scheme 5 Synthesis of 7d.
TMSOTf as promoter as acceptor gave 24. The acetonide groups were then removed by heating in 80% acetic acid and the deprotected intermediate then acetylated to obtain a per-O-acetylated disaccharide, where the glucose residue was in the pyranose form. Next, treatment of this per-O-acetate with azidotrimethylsilane in the presence of a Lewis acid gave a b-azide intermediate and subsequent catalytic hydrogenation of the azide gave 25 as a mixture of anomers. Coupling of 25 using freshly recrystallised terephthaloyl chloride proceeded in 84% yield to produce the acetylated dimeric precursor. Subsequent de-O-acetylation using Zemplén conditions proceeded smoothly to give 7d; 26 was also isolated as a by-product from this reaction sequence. This sequence was overall more efficient than that described for preparation of 7c previously.
5c
The synthesis (not shown) of 11 was achieved by glycosidation of 15 with tetraethylene glycol as the nucleophile and subsequent deprotection. Having completed the synthetic procedures, we next calculated spatial aspects of ligand presentation.
Spatial parameters of ligand presentation
The spatial way that mannose residues are presented on the macrocyclic derivatives 2a and 4a was inferred computationally. It was expected that the mobility of mannose residues in 2a and 4a/4b would be significantly more restricted than in both 1a and 3a. Cyclophane analogues derived from phenylenediamine which incorporate allyl glycosides have been noted to be rigid.
10a
The macrocyclic scaffold of 2a contains two internal b-linked glucuronic acid residues, whereas that in 4a contains two internal a-linked glycosides. The effect of these scaffold configurational differences on the spatial parameters of mannose presentation was explored by molecular modelling. Low-energy conformations of the core scaffold structures were first generated using conformational searching techniques and energy minimization in Macromodel. The mannose residues were then incorporated so that glycosidic bond torsion angles defining the linkage between the mannose residues and the glucuronic acid residue were consistent with low-energy structures for related disaccharides, which had been calculated using the OPLS-AA force field in Macromodel.
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One of the mannose residues of 2a was then superimposed with one of the mannose residues of 4a, and the overlapped model structures are shown in Fig. 2 . The modeling shows that the spatial relationship between the two mannose residues in 2a is clearly distinct from that in 4a. The distance (Man C-1 to Man C-1) between the mannose residues in 2a is 15.4 Å , whereas the equivalent distance in 4a is 13.0 Å . Two other parameters were selected to define ligand spatial presentation: (a) the dihedral angle defined by the glycosidic bonds to the two mannose residues (C1-O1-O1-C1); (b) the dihedral angle defined by C4-C1-C1-C4 of the mannose residues. For 2a these parameters were 83
• and -66
• , respectively, whereas for 4a these correspondingly were -2
• and -141
• . To next prove bioactivity of the prepared compounds and to trace structure-activity correlations of biological relevance cell-binding assays were systematically performed.
Cell assays
Biological responses are triggered by binding of lectins to cell surface glycans. Obviously, this process needs to be impaired for triggering a therapeutic effect. Labelling of a lectin without activity impairment generates a reliable tool to monitor its association with cell surfaces. The extent of carbohydrate-dependent cell binding is experimentally determined by fluorescent staining in FACScan analysis, obtaining the percentage of positive cells and signal intensity on a logarithmic scale as read-out, as presented in Fig. 3-7 . The binding of the labelled lectin will shift the curve representing the staining profile of each lectin-exposed cell population from the position of the control (given as shaded area in each Figure) , and presence of an effective inhibitor will move the curve back into the direction of the control. In other words, the two mentioned staining parameters in the graphs will be lowered, if a glycocompound successfully competes with the lectin's docking sites on the cell surface. The result of this competition is best evaluated at a subsaturating lectin concentration in the linear range of concentration dependence, in this case at 1 mg ml -1 . It is mandatory to run the assay with aliquots of the same cell batch. As essential controls for the probe's activity, we first ascertained the respective effects of the known haptenic monosaccharides mannose and glucose at this ConA concentration on binding to colon adenocarcinoma cells. Both sugars affected extent of lectin binding (Fig. 3A,B) . The direct comparison at 2 mM inhibitor concentration revealed superiority of mannose relative to glucose (Fig. 3C ). The measured relative potencies of the two monosaccharide inhibitors reflected their known activities in other assays.
6a Galactose, used as osmolarity control, as expected, did not interfere with lectin activity (not shown). These experimental series validated the assay so that the panel of test compounds could be systematically examined.
In principle, derivatization and attachment of mannose to a variety of different scaffolds did not impair the bioactivity of the mannose residue. However the nature of the scaffold employed did have an influence. Routinely, aliquots of cell batches were studied with the whole panel of compounds to avoid any influence of differences among individual cell preparations. Gradual dif- labelled ConA. The control value of cell positivity by the second-step reagent in the absence of lectin is given as shaded area, the 100% value (lectin staining in the absence of inhibitor) as black line. Numbers characterizing staining (percentage of positive cells/mean fluorescence intensity) in each panel are always given in the order of the given listing. A/B: Inhibition of lectin binding by increasing concentrations of mannose (A: 1 mM, 2 mM, 4 mM, 10 mM, 20 mM) and glucose (B: 1 mM, 2 mM, 4 mM, 10 mM, 20 mM). C: Staining parameters in the presence of 2 mM mannose and 2 mM glucose. D: Staining parameters in the presence of 0.5 mM sugar in compounds 6a, 1a, 9 and 11 compared to those at 2 mM free mannose in (C). E: Staining parameters in the presence of 0.5 mM sugar in compounds 2a, 5a, 4b and 4a compared to those at 2 mM free mannose in (C). F: Staining parameters in the presence of 0.1 mM sugar in compounds 6a, 2a and 1a compared to those at 0.2 mM free mannose. ferences in binding affinities for synthetic ligands were therefore noted in comparative analyses exemplarily illustrated in Fig. 3D , E. The presentation of mannose in the context of the derivatives increased the lectin-blocking capacity more than fivefold based on the sugar concentration in the assay, with the strongest effects seen already with the monomer 6a (Fig. 3F) . Macrocycle 2a was rather effective and surpassed the level of inhibition observed for the mannose-bearing cyclophanes 4a and 4b (Fig. 3E) . The acyclic and more flexible derivative 1a was also active (Fig. 3D) . In direct comparison at a normalized sugar concentration of 0.1 mM, the establishment of a rigid scaffold for sugar presentation consistently resulted in an increase in inhibition of ConA binding compared to the less rigid scaffold (2a more potent than 1a) (Fig. 3F) . Among the terephthalamides compound 9 gave the highest level of blocking lectin binding, surpassing that of the increasingly flexible bisubstituted tetraethylene glycol 11 (Fig. 3D ) and other terephthalamides 7 and 8. In order to next infer dependence on the type of lectin a respective experimental series were investigated with another leguminous lectin (Fig. 4) . When using the closely related lectin Pisum sativum agglutinin as a probe, the relative potencies did indeed not remain constant. The monomer 6a was less active than free mannose (not shown). Macrocycle 4a was a comparatively stronger inhibitor than 2a and also its acyclic analogue 3a, but only barely displaying the inhibitory efficiency of free mannose (Fig. 4B) . Terephthalamide-based scaffolds also proved to be bioactive, with 9 being again more potent than 7 and 8, demonstrating the significant impact on linkage types (Fig. 4B ). Taking these data into account it thus does not appear to be valid to extrapolate data within a lectin family. To next reveal whether the inhibitory potency on ConA will depend on the glycan profile, we performed three series of experiments.
First, we treated the colon cancer cells with mannosidase I inhibitor 1-deoxymannojirimycin to shift glycan processing from generating complex-type to high-mannose-type glycosylation and, indeed, obtained the expected increase in ConA binding (Fig. 5A) . Thus, we could address the issue on the relationship of inhibitory potency to a variation in glycan display and subsequently examined each compound's activity. Overall, the respective measurements quantitatively yielded a rather similar distribution of activity when compared to assays carried out with the untreated cells. Of note, macrocycle 2a showed increased activity with a more than 2.5-fold difference relative to its open form 1a (please note: plots given in Fig. 5B were recorded at 0.2 mM mannose concentration for compound 2a vs. 0.5 mM for compound 1a). This result intimates again the enhanced potential of a suitable macrocyclic compound to block binding at increased cell surface ligand density. Activity grading among terephthalamide-based Fig. 5 Staining of cells of the human colon adenocarcinoma line SW480 after treatment with 1-deoxymannojirimicin by 1 mg ml -1 labelled ConA (for further details, please see the legend to Fig. 3) . A: Staining parameters in the absence (dashed) and in the presence of 1-deoxymannojirimycin (black) as well as its inhibition by the presence of 0.5 mM, 2 mM and 10 mM mannose, respectively. B: Inhibition of lectin binding by 0.2 mM sugar in compound 2a, 0.5 mM sugar in compound 1a, 0.2 mM sugar in compound 6a and 0.5 mM sugar in compound 8 compared to the following reference data when using free sugar: 62%/20 at 0.5 mM mannose and 42%/11.9 at 2 mM mannose.
compounds remained similar, with bivalent compound 8 still proving slightly more active than free mannose (Fig. 5B ).
Second, we tested a cell system from a different tumour type, using the human pancreatic carcinoma line Capan-1. Commonly, cell surface glycosylation changes among different tumour types. The bioactivity profiles of the test compounds disclosed a notable activity for terephthalamide derivative 9 and tetraethylene glycol 11 (Fig. 6) . However, macrocyclic ring-closure led only to a slight improvement of the activity of compound 2a compared to open form 1a (Fig. 6A, B) ; this contrasted to that observed for the colon adenocarcinoma cells, especially after increasing high-mannosetype surface glycosylation. The open form 1a displayed a value close to that observed for the mannose reference at 22%/10.5, corroborating the concept for a dependence of relative compound activity on cell-surface characteristics. Besides altering the cell-type and density of ligands on a cell surface, the affinity of a lectin for a cell type can also be manipulated. A method to increasing ConA affinity for a cell involves truncation of complex-type N-glycans so that terminal GlcNAc moieties are found in the branches.
6b,c We thus finally tested a glycosylation mutant of Chinese hamster ovary (CHO) cells with impaired galactosylation (Lec8). Whereas ligand density had previously appeared to alter reactivity to rigid macrocycle 2a, the presentation of high-affinity ligands on CHO cells led to no significant shifts relative to that observed in assays with colon cancer cells. As noted before, the monomeric derivative 6a was active, and the inhibitory grading including the 2a/1a comparison remained rather constant, as exemplarily illustrated in Fig. 7 . Terephthalamide 9 was again active. Thus for two different cell types, increasing the density of mannose residues and presenting A: Staining with increasing concentrations of labelled ConA (0.2 mg ml -1 , 0.5 mg ml -1 , 1 mg ml -1 and 2 mg ml -1 ). B: Inhibition of lectin binding at a concentration of 1 mg ml -1 by 0.5 mM sugar in compounds 2a, 9 and 1a compared to 1 mM free mannose and the control in the absence of sugar. high-affinity ligands by N-glycan truncation were tested and the results revealed a consistent effect of both scaffold rigidity and structure on inhibitory activity. Particular rigid structures based on glycocyclophane scaffolds, as the cell based tests with the two tested leguminous lectins reveal, may selectively improve blocking of cell binding, as parallel assays with the compound pairs 1a/2a and 3a/4a documented. Of practical value, the outlined routes to tailor cell surface glycosylation are proposed to be of general importance for testing glycan derivatives and glycoclusters.
Conclusion
Our report addresses the question of potency in cell assays of bivalent mannosides presented on a variety of scaffolds. We specifically compared compounds based on both flexible and rigid scaffolds and also compared differing spatial arrangement of ligands presented on two subtly distinctive rigid macrocyclic scaffolds. Toward this end, we reported the facile synthesis of two types of phenylenediamine-based glycocyclophanes and improvements to preparing derivatives based on the terephthalamidebased scaffold. Bioactivity was tested in cell assays, revealing consistent lectin-binding properties of the derivatives. Obviously, macrocycles 12 can serve as an effective ligand-presenting scaffold, as also documented for tetraaza[6.1.6.1]paracyclophane or also cyclic peptides as macrocyclic frameworks.
13,14 Also, terephthalamide derivatives were shown to be active. Herein, we move beyond common haemagglutination, precipitation or solid-phase data to let the glycocompounds compete with cell surface glycans for lectin binding. The presented results therefore extend the available data on bivalent compounds and ConA binding, delineating an impact of intra-mannosyl distance and linkage type, e.g. obtained with diamine cores.
15 The reduction of the inherent level of flexibility appeared to have a favorable impact especially for cells displaying a high ligand density, and the structure of the macrocycle can modulate inhibitory potency in interlectin comparison (ConA/PSA). In addition to conformational restraint the three-dimensional presentation of the ligands, highly dependent on the scaffold employed, could factor into differences observed in the assay system.
Of general importance beyond the nature of this model, we have set up a strategy for cell assays, which minimizes the risk for invalid generalizations and reaches high sensitivity to probe influence of the nature of glycomic profiles. It consists of two different lines and manipulations of the glycomic profile by recruiting an inhibitor for glycan processing and a glycosylation mutant. Because interference with cell binding is a medically relevant parameter and tissue lectins can target distinct ligands with context-dependent glycosylation, e.g. as recognition signals in adhesion, induction of apoptosis or glycoprotein routing, 2,4,16 this approach is proposed to find applications in studies on endogenous lectins.
Experimental Allyl 2,3,4,6-tetra-O-acetyl-a-D-mannopyranosyl-(1→3)-2,4-di-Oacetyl-1-O-allyl-b-D-glucopyranosiduronate 14
Ester 13 20 (74 mg, 0.21 mmol) and 15 (112 mg, 0.22 mmol) were dissolved in dry dichloromethane (5 mL) and molecular sieves were added and the mixture was stirred at room temp and under N 2 for 20 min. The mixture was then cooled on an ice bath and 0.04 M TMSOTf in dry dichloromethane (0.5 mL, 0.02 mmol) was then added dropwise. Stirring was continued on ice for 30 min and solid NaHCO 3 (90 mg) was then added and the mixture stirred for a further 5 min. Filtration was followed by removal of solvent under diminished pressure. Chromatography (dichloromethaneEtOAc, 5 : 1) of the residue gave the protected disaccharide as a white solid (107 mg, 78%); [a] 20.9, 20.8, 20.7, 20.7, 20.6, 20.6 (each CH 3 ); HRMS (ES): calcd 711.2112 [M+Na] + , found 711.2087; IR (film from dichloromethane): 3369, 3197, 2981, 1751, 1608, 1373, 1224 cm -1 . To the protected disaccharide (107 mg, 0.155 mmol) in dry acetonitrile (1 mL) at 0
• C Pd(Ph 3 P) 4 (18 mg, 0.015 mmol) followed by pyrrolidine (12 mL, 0.16 mmol) were added under N 2 and the mixture was stirred at 0
• C for 25 min and then filtered through celite. The solvent was removed under diminished pressure and the yellow residue was dissolved in EtOAc and washed with water. The aq phase was acidified to pH = 4 with Amberlite-H + resin and then filtered. The filtrate was extracted with EtOAc (4 ¥ 10 mL) and the combined organic extracts were dried (MgSO 4 ), filtered and the solvent was removed to give 14 as a pale yellow foam (65 mg, 65%); [a] 20.9, 20.8, 20.8, 20.7, 20.6, (each OCOCH 
1,4-Di-[(N-(1-methoxycarbonyl)methylamino-2-oxoethyl)-2,3,4,6-tetra-O-acetyl-a-D-mannopyranosyl-(1→3)-2,4-di-O-acetyl-1-Oallyl-b-D-glucopyranuronamido]benzene 20a
Formaldehyde ( 169.8, 169.7, 169.4, 168.2, 166.6 (each CO), 142.2 (aromatic C), 133.4 (CH), 129.4 (aromatic CH), 117.7 (CH 2 ), 100.0, 99.7, 80.5, 77.4, 71.9, 71 .0 (each CH), 70.1 (CH 2 ), 69. 8, 69.7, 69.0, 65.6 (each CH) 3631-3374, 2966, 1751, 1670, 1510, 1438, 1373, 1223, 1040 cm -1 .
1,4-Di-[(N-(1-methoxycarbonyl)methylamino-2-oxoethyl)-a-Dmannopyranosyl-(1→3)-1-O-allyl-b-D-glucopyranuronamido]-benzene 1a
To a flask containing potassium cyanide (5.4 mg, 0.083 mmol), which had been pre-dried under high vacuum, a solution of 20 (23 mg, 0.014 mmol) (s, 4H, aromatic H), 2H, CH=), 4H, CH 2 =), 5.18 (s, 2H, J 20.1, 2H, NCH 2 CONH), J 20.1, 2H, NCH 2 CONH), J 8.1, 2H, 2H, OCH 2 ), J 8.4, 2H, 2H, OCH 2 J 8.7, 2H, aromatic H), J 8.7, 2H, aromatic H), 1H, CH=), 2H, CH Di-[(N-(1-methoxycarbonyl)methylamino-2-oxoethyl)-a-D- 
mannopyranosyl-(1→3)-1-O-allyl-a-D-glucopyranuronamido]-benzene 3a
Deprotection of 21a (7 mg, 4 
1,4-Di-[(N-(1-methoxycarbonyl)methylamino-2-oxoethyl)-a-Dmannopyranosyl-(1→3)-1-azido-1-deoxy-b-Dglucopyranuronamido]benzene 5a
The protected dimer 22 (24 mg, 0 
Glycocyclophane 2a
A degassed solution of the diamide 20a (47 mg, 0. 029 mmol) in dry dichloromethane (17 mL, 1.7 mM) 169.5, 169.1, 167.8, 166.5, 166.4 (each CO) , 141.9 (aromatic C), 131.0 (CH=), 129.0, 128.6 (each aromatic CH), 100.0, 99.7, 99.4, 80.4, 72.4, 71.7, 71.5, 71.2, 69.9, 69.5, 69.4, 69.0, 68.9, 68.7, 68.6, 67.7, 66.2, 65.3, 65 .2 (C-2 to C-5 GlcA and Man), 63.9, 62.6 (each OCH 2 ), 61.6, 61.5 (each C-6 Man), 55.2 (NCH 2 CO), 52.3 (CO 2 CH 3 ), 41.1 (NHCH 2 CO 2 ), 20.9 (2 s), 20.8 (2 s), 20.7 (2 s), 20.6 (each COCH 3 ); HRMS (ES): [M+Na] + calcd 1621.4716 found 1621.4768; IR (film from dichloromethane): 3622-3401, 2963, 1750, 1660, 1373, 1225, 1041 cm -1 . To this mixture (40 mg, 0.014 mmol) in EtOAc (2 mL), 10% Pd-C (6 mg) was added and the reaction mixture was stirred at room temp under H 2 . The mixture was then filtered through celite and the solvent removed under diminished pressure. Chromatography (dichloromethaneMeOH, 97 : 3) gave the protected glycophane (37 mg, 92%); R f 0.17 (dichloromethane-MeOH, 95 : 5); [a] 169.9, 169.7, 169.0, 167.8, 166.4 (each CO), 142.6 (broad signal, aromatic C), 130.2, 129.8 (broad signals, each aromatic CH), 100.8, 99.9 (C-1 GlcA and Man), 80. 9, 77.7, 69.6, 69.57, 69.5, 69.4, 69.0, 65 .2 (2 s) (C-2-C-5 GlcA and Man, OCH 2 ), 61.5 (C-6 Man), 52.3 (NCH 2 CO), 52.3 (CO 2 CH 3 ), 41.1 (NHCH 2 CO 2 ), 20.9, 20.8 (2 s), 20.7 (2 s), 20.6 (each COCH 3 ); IR (film from dichloromethane): 3613-3405, 2959, 1748, 1655, 1509, 1437, 1373, 1259, 1223 
